Annual EBITDA
-$156.77 M
-$24.53 M-18.55%
December 31, 2023
Summary
- As of February 7, 2025, AUTL annual EBITDA is -$156.77 million, with the most recent change of -$24.53 million (-18.55%) on December 31, 2023.
- During the last 3 years, AUTL annual EBITDA has risen by +$3.83 million (+2.38%).
- AUTL annual EBITDA is now -1028.00% below its all-time high of -$13.90 million, reached on September 30, 2016.
Performance
AUTL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$69.45 M
-$23.30 M-50.48%
September 30, 2024
Summary
- As of February 7, 2025, AUTL quarterly EBITDA is -$69.45 million, with the most recent change of -$23.30 million (-50.48%) on September 30, 2024.
- Over the past year, AUTL quarterly EBITDA has dropped by -$37.83 million (-119.61%).
- AUTL quarterly EBITDA is now -2889.58% below its all-time high of -$2.32 million, reached on December 31, 2022.
Performance
AUTL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$192.51 M
-$29.97 M-18.44%
September 30, 2024
Summary
- As of February 7, 2025, AUTL TTM EBITDA is -$192.51 million, with the most recent change of -$29.97 million (-18.44%) on September 30, 2024.
- Over the past year, AUTL TTM EBITDA has dropped by -$37.14 million (-23.91%).
- AUTL TTM EBITDA is now -575.06% below its all-time high of -$28.52 million, reached on March 31, 2019.
Performance
AUTL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AUTL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.6% | -119.6% | -23.9% |
| 3 y3 years | +2.4% | -78.2% | -61.0% |
| 5 y5 years | -543.4% | -78.2% | -61.0% |
AUTL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -18.6% | at low | -2889.6% | at low | -69.2% | at low |
| 5 y | 5-year | -18.6% | +2.4% | -2889.6% | at low | -69.2% | at low |
| alltime | all time | -1028.0% | +2.4% | -2889.6% | at low | -575.1% | at low |
Autolus Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$69.45 M(+50.5%) | -$192.51 M(+18.4%) |
| Jun 2024 | - | -$46.15 M(+45.9%) | -$162.54 M(+4.6%) |
| Mar 2024 | - | -$31.62 M(-30.2%) | -$155.37 M(-0.9%) |
| Dec 2023 | -$156.77 M(+18.5%) | -$45.29 M(+14.7%) | -$156.77 M(+37.8%) |
| Sep 2023 | - | -$39.48 M(+1.3%) | -$113.80 M(-4.9%) |
| Jun 2023 | - | -$38.98 M(+18.0%) | -$119.61 M(-5.4%) |
| Mar 2023 | - | -$33.02 M(+1321.5%) | -$126.43 M(-4.4%) |
| Dec 2022 | -$132.24 M(-0.2%) | -$2.32 M(-94.9%) | -$132.24 M(-12.3%) |
| Sep 2022 | - | -$45.28 M(-1.1%) | -$150.85 M(+5.9%) |
| Jun 2022 | - | -$45.80 M(+18.0%) | -$142.49 M(+6.4%) |
| Mar 2022 | - | -$38.83 M(+85.5%) | -$133.98 M(+1.1%) |
| Dec 2021 | -$132.47 M | -$20.93 M(-43.3%) | -$132.47 M(-14.7%) |
| Sep 2021 | - | -$36.93 M(-1.0%) | -$155.32 M(-2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$37.29 M(-0.1%) | -$159.63 M(-0.3%) |
| Mar 2021 | - | -$37.33 M(-14.7%) | -$160.10 M(+0.0%) |
| Dec 2020 | -$160.60 M(+19.5%) | -$43.78 M(+6.2%) | -$160.07 M(+6.0%) |
| Sep 2020 | - | -$41.24 M(+9.2%) | -$151.03 M(+4.7%) |
| Jun 2020 | - | -$37.75 M(+1.2%) | -$144.27 M(+0.8%) |
| Mar 2020 | - | -$37.30 M(+7.4%) | -$143.18 M(+6.5%) |
| Dec 2019 | -$134.40 M(+451.6%) | -$34.74 M(+0.8%) | -$134.40 M(+34.9%) |
| Sep 2019 | - | -$34.48 M(-6.0%) | -$99.66 M(+52.9%) |
| Jun 2019 | - | -$36.66 M(+28.6%) | -$65.18 M(+128.6%) |
| Mar 2019 | - | -$28.52 M | -$28.52 M |
| Dec 2018 | -$24.36 M(-56.4%) | - | - |
| Sep 2018 | -$55.82 M(+149.1%) | - | - |
| Sep 2017 | -$22.41 M(+61.2%) | - | - |
| Sep 2016 | -$13.90 M | - | - |
FAQ
- What is Autolus Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Autolus Therapeutics?
- What is Autolus Therapeutics annual EBITDA year-on-year change?
- What is Autolus Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Autolus Therapeutics?
- What is Autolus Therapeutics quarterly EBITDA year-on-year change?
- What is Autolus Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Autolus Therapeutics?
- What is Autolus Therapeutics TTM EBITDA year-on-year change?
What is Autolus Therapeutics annual EBITDA?
The current annual EBITDA of AUTL is -$156.77 M
What is the all time high annual EBITDA for Autolus Therapeutics?
Autolus Therapeutics all-time high annual EBITDA is -$13.90 M
What is Autolus Therapeutics annual EBITDA year-on-year change?
Over the past year, AUTL annual EBITDA has changed by -$24.53 M (-18.55%)
What is Autolus Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AUTL is -$69.45 M
What is the all time high quarterly EBITDA for Autolus Therapeutics?
Autolus Therapeutics all-time high quarterly EBITDA is -$2.32 M
What is Autolus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AUTL quarterly EBITDA has changed by -$37.83 M (-119.61%)
What is Autolus Therapeutics TTM EBITDA?
The current TTM EBITDA of AUTL is -$192.51 M
What is the all time high TTM EBITDA for Autolus Therapeutics?
Autolus Therapeutics all-time high TTM EBITDA is -$28.52 M
What is Autolus Therapeutics TTM EBITDA year-on-year change?
Over the past year, AUTL TTM EBITDA has changed by -$37.14 M (-23.91%)